Abstract

Senescence is an important determinant of treatment outcome in cancer therapy. In the present study, we show that knockdown of the inwardly rectifying K(+) channel Kir2.2 induced growth arrest without additional cellular stress in cancer cells lacking functional p53, p16, and/or Rb. Kir2.2 knockdown also induced senescence-associated β-galactosidase activity and upregulated senescence marker proteins in multiple cancer cell lines derived from different tissues, including prostate, stomach, and breast. Interestingly, knockdown of Kir2.2 induced a significant increase in reactive oxygen species (ROS) that was accompanied by cell cycle arrest, characterized by significant upregulation of p27, with concomitant downregulation of cyclinA, cdc2, and E2F1. Kir2.2 knockdown cells displayed increased levels of PML bodies, DNA damage (γH2AX) foci, senescence-associated heterochromatin foci, mitochondrial dysfunction, secretory phenotype, and phosphatase inactivation. Conversely, overexpression of Kir2.2 decreased doxorubicin-induced ROS accumulation and cell growth inhibition. Kir2.2 knockdown-induced cellular senescence was blocked by N-acetylcysteine, indicating that ROS is a critical mediator of this pathway. In vivo tumorigenesis analyses revealed that tumors derived from Kir2.2 knockdown cells were significantly smaller than those derived from control cells (P < 0.0001) and showed a remarkable increase in senescence-associated proteins, including senescence-associated β-galactosidase, p27, and plasminogen activator inhibitor-1. Moreover, the preestablished tumors are reduced in size after the injection of siKir2.2 (P = 0.0095). Therefore, we propose for the first time that Kir2.2 knockdown induces senescence of cancer cells by a mechanism involving ROS accumulation that requires p27, but not Rb, p53, or p16.

Highlights

  • Senescence, characterized by specific physiological and morphological changes, including reduced proliferation, shortened telomeres, a flat and enlarged cell shape, and the appearance of senescence-associated β-galactosidase (SA-β-Gal) activity, is considered a major determinant of treatment outcome in cancer therapy [1,2,3]

  • In a previous cDNA microarray analysis designed to identify growth arrest-associated genes that might contribute to the molecular mechanisms that allow malignant cells to escape senescence, we found that Kir2.2 was selectively down-regulated in association with doxorubicin-induced cellgrowth arrest

  • We found that Kir2.2 knockdown alone induced senescence-like cell-cycle arrest in a variety of cancer cell lines, including those established from prostate (PC-3, DU145, and LNCaP), stomach (MKN74, SNU638 and SNU668) and breast (MCF7, SK-BR3, and T47D)

Read more

Summary

Introduction

Senescence, characterized by specific physiological and morphological changes, including reduced proliferation, shortened telomeres, a flat and enlarged cell shape, and the appearance of senescence-associated β-galactosidase (SA-β-Gal) activity, is considered a major determinant of treatment outcome in cancer therapy [1,2,3]. In previous studies designed to better understand how malignant cells escape cellular senescence, we sought to define the genes that control this pathway [7,8,9]. In a cDNA microarray hybridization analysis, we found that doxorubicin-induced senescence selectively inhibited a set of genes that included the inwardly rectifying K+ channel Kir2.2. K+ channels have been implicated in a variety of physiologic functions, including proliferation, differentiation, and apoptosis. The role of K+ channels in proliferation has been well documented in many types of normal and malignant cells, including lymphocytes [10], breast cancer cells [11,12], colon cells [13], and prostate cancer cells [14]. Previous studies have shown that K+ channels may be associated with cancer, the precise functions of Kir2.2 in senescence and/or carcinogenesis remain unknown

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call